Abbott Laboratories (NYSE:ABT) markets everything from Similac baby formula to cataract surgery equipment and its restructuring itself in order to spark revenue growth.
Abbott is a long-standing member of the S&P 500 dividend aristocrats, a collection of companies with a proud history of dividend increases, so investors are right to wonder if sluggish sales tied to a recall last fall are ready to rebound.
In the following slideshow, I include the most important takeaways from Abbott's second-quarter results and highlight the key reasons Abbott may find the second half of this year is better than the first.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
4 Things to Do Before Tax Day
Doing this will give you a much easier time completing your tax returns.
No Holiday Reprieve for 2 of the Biggest Retail Train Wrecks
Most department store chains have posted surprisingly strong results for the 2017 holiday season. However, these perennial laggards couldn't capitalize on the uptick in consumer spending.
3 Stocks That Could Put Amazon's Returns to Shame
These three tickers could be better bets than Amazon for new investors right now.